PEG

ICE Announces Plans to Implement EU Market Correction Mechanism and Related Price Cap on TTF Natural Gas

Retrieved on: 
Friday, January 27, 2023
Professional Services, Data Analytics, Oil, Gas, Energy, Finance, Fintech, Banking, Transfer, Insurance, Natural gas, Intercontinental, SVP, NYSE, TTF, Face, NBP, LNG, MCM, Risk, PEG, Laws of the Game, Regulation, Risk management, European, ICE, Intercontinental Exchange

Intercontinental Exchange, Inc. (NYSE: ICE), a leading global provider of data, technology, and market infrastructure, today announced how it intends to implement the European Union’s Market Correction Mechanism Regulation (MCM Regulation) and related price cap on TTF natural gas derivatives, in time for entry into force of the regulation.

Key Points: 
  • Intercontinental Exchange, Inc. (NYSE: ICE), a leading global provider of data, technology, and market infrastructure, today announced how it intends to implement the European Union’s Market Correction Mechanism Regulation (MCM Regulation) and related price cap on TTF natural gas derivatives, in time for entry into force of the regulation.
  • For details on the intended Rulebook changes and related guidance in respect of the MCM Regulation, please see https://www.theice.com/endex/circulars .
  • This may mean that settlement prices of TTF futures and options may deviate from the price cap when it is not reflecting fair market value.
  • This will provide market participants with optionality in the event the natural gas price rises, and the risk of the MCM price cap being triggered increases.

Monarch Private Capital Finances Historic Preservation of Phoenix’s First 10-Story Building

Retrieved on: 
Thursday, January 26, 2023
Chase Field, Policy, Education, Arizona State University, Monarch, HTC, Luhr, University, City, PEG, Luhrs Building, ESG, Transport, Arizona Diamondbacks, Central Avenue, Sky Harbor Airport, Jefferson Street, Northern Arizona University, Growth, Moxy, Culture, University of Arizona, Hotel, Phoenix

The Luhrs Building was constructed in 1924 in Phoenix, Arizona, by George H.N.

Key Points: 
  • The Luhrs Building was constructed in 1924 in Phoenix, Arizona, by George H.N.
  • The 10-story, 108,000-square-foot structure was the tallest building in Phoenix at the time and the largest commercial building between El Paso and Los Angeles.
  • The club featured rooms for lodging, a library, billiards room, kitchen, dining rooms, office space and even slot machines.
  • PEG Companies , a leading full-service commercial real estate investor, purchased the Luhrs Building in 2019 to refashion the property into a vibrant, contemporary hotel.

Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates

Retrieved on: 
Wednesday, January 4, 2023
Cancer, Organic acid, LNP, Amine, Daewoong Pharmaceutical, Pharmacokinetics, RNA transfection, Research, PEG, Patient, KRX, Therapy, Quality of life, RNA, Lipid, Vaccine, Pharmaceutical industry

Research collaboration leverages Oncorus’ proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong’s mRNA expertise

Key Points: 
  • Research collaboration leverages Oncorus’ proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong’s mRNA expertise
    ANDOVER, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, and Daewoong Pharmaceutical Co., Ltd. (KRX: 069620), a leading South Korean pharmaceutical company, today announced a research collaboration for the discovery and development of novel lipid nanoparticle (LNP) formulations for mRNA drug candidates.
  • Under the terms of the collaboration, Oncorus and Daewoong will conduct joint research to identify and evaluate formulations of Daewoong’s mRNAs encapsulated in Oncorus’ proprietary LNPs.
  • Oncorus will develop formulated drug candidates at its state-of-the-art manufacturing facility in Andover, Massachusetts.
  • In multiple preclinical models involving repeat intravenous (IV) dosing, Oncorus’ formulations have demonstrated improved tolerability, an enhanced therapeutic window and consistent pharmacokinetics compared to approved formulations.

Nexii and PEG Companies Complete New Courtyard by Marriott Hotel

Retrieved on: 
Tuesday, December 20, 2022
Partnership, Climate, Musqueam Indian Band, Strategy, PEG, Building material, Carbon, Life, 3D printing, Nexus

VANCOUVER, British Columbia, Dec. 20, 2022 (GLOBE NEWSWIRE) -- (Unceded Territories of the Musqueam, Squamish and Tsleil-Waututh Nations)--Green construction company Nexii Building Solutions today announced the completion of a new Courtyard by Marriott hotel in Nanaimo on Vancouver Island, built in partnership with PEG Companies (PEG).

Key Points: 
  • VANCOUVER, British Columbia, Dec. 20, 2022 (GLOBE NEWSWIRE) -- (Unceded Territories of the Musqueam, Squamish and Tsleil-Waututh Nations)--Green construction company Nexii Building Solutions today announced the completion of a new Courtyard by Marriott hotel in Nanaimo on Vancouver Island, built in partnership with PEG Companies (PEG).
  • PEG Companies, which planned and developed the hotel, partnered with Nexii to construct the building’s exterior envelope.
  • PEG selected Nexii due to its innovative technology that significantly reduced the climate impact of the hotel’s construction.
  • Nexii manufactured 750 unique structural panels for the nine-story hotel at its production facility in Squamish, British Columbia.

Majors Management Announces Acquisition of the Maritime Farms Convenience Stores of Maritime Energy in Maine

Retrieved on: 
Wednesday, December 21, 2022
PEG, Maritime, Valero, Shell, Citgo, Alon, TS State of Maine, Major, Exxon, BP, Fuel, Marathon, Mobil, Acquisition, Propane, Petroleum, Sunoco, Texaco

LAWRENCEVILLE, Ga., Dec. 21, 2022 /PRNewswire/ -- Majors Management, LLC, and its affiliates ("Majors") of Lawrenceville, GA, a recognized retail petroleum industry leader, announces the successful acquisition of the Maritime Farms convenience stores of Maritime Energy ("Maritime").

Key Points: 
  • LAWRENCEVILLE, Ga., Dec. 21, 2022 /PRNewswire/ -- Majors Management, LLC, and its affiliates ("Majors") of Lawrenceville, GA, a recognized retail petroleum industry leader, announces the successful acquisition of the Maritime Farms convenience stores of Maritime Energy ("Maritime").
  • With 13 convenience locations with full delis located in Midcoast Maine, the acquisition represents Majors' first entry into the State of Maine.
  • "With the acquisition of the Maritime sites, Majors now operates across the East Coast of the United States from Florida to Maine," stated Majors' President, Ben Smith.
  • Lawrenceville, GA-based Majors Management, LLC is an owner, developer and operator of convenience stores and a distributor of high-quality branded motor fuels.

Polymer protection for vaccines and drugs

Retrieved on: 
Friday, December 9, 2022
Anaphylaxis, Allergy, Sudden death, Protein, Science and Technology of Advanced Materials, Miho Teramura, Liposome, Water, Science, Antibody, PEG, National Institute of Advanced Industrial Science and Technology, Skin, Nausea, Unconsciousness, Vaccine, Human, MPC, Advanced Materials, Immune system, Research, Risk, Blood, COVID-19, Patient, AIST, STAM, Pharmaceutical industry

TSUKUBA, Japan, Dec 9, 2022 - (ACN Newswire) - A biocompatible polymer could help deliver vaccines and drugs with reduced risk of the rare dangerous adverse reaction called anaphylaxis.

Key Points: 
  • TSUKUBA, Japan, Dec 9, 2022 - (ACN Newswire) - A biocompatible polymer could help deliver vaccines and drugs with reduced risk of the rare dangerous adverse reaction called anaphylaxis.
  • Until now, the polymer of choice for encasing and delivering vaccines has been poly(ethylene glycol) (PEG).
  • The alternative polymer is a form of fatty biomolecule called a lipid, and is conjugated to 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer.
  • Provided the animal and subsequent clinical trials go well, the technology should offer opportunities for delivering drugs into the body, in addition to vaccines.

Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis

Retrieved on: 
Monday, December 12, 2022
HNC, GC4419, Head, Cisplatin, Privacy, Patient, Annual report, Hospital, Pancreatic cancer, Incidence, Failure, Health, Manganese, Food, FDA, Lung cancer, PEG, AE, Safety, Cancer, Mucositis, New Drug Application, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Prognosis, Large-cell lung carcinoma, Radiation, NDA, Breakthrough therapy, Therapy, Risk, COVID-19, SOM, Pharmaceutical industry, Medical imaging

The FDA has granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy.

Key Points: 
  • The FDA has granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy.
  • “Approximately 42,000 patients with HNC undergo standard-of-care radiotherapy every year in the U.S. and are at risk of developing SOM.
  • Meaningful reduction in the number of patients who developed the most severe form of SOM (Grade 4) was also observed.
  • Galera’s selective dismutase mimetic product candidate avasopasem manganese (avasopasem, or GC4419) is being evaluated for radiotherapy-induced toxicities.

PSE&G: Two First Place J.D. Power Rankings in 2022

Retrieved on: 
Wednesday, December 14, 2022
Big data, Customer service, Gas, PEG, Communication, J.D. Power, Natural gas, Mid-Atlantic (United States), Research, Consumer, Edison Electric Institute, PSEG, NYSE, Intelligence, Artificial intelligence, Multimedia, Safety, Dow Jones, Privilege escalation, Partner, PSE, Electric utility, Construction, Public utility, Renewable energy, Retail, Health insurance, Marketing, Online shopping

NEWARK, N.J., Dec. 14, 2022 /PRNewswire/ -- PSE&G has been recognized again for delivering award-winning customer satisfaction. As New Jersey's largest combination utility, PSE&G provides electric service for 2.3 million customers and natural gas service for 1.9 million customers. PSE&G is the first combination utility to ever receive the highest customer satisfaction ranking by both its natural gas and electric customers in the same year among the large utilities in the east. As compared to the utilities that were measured in the J.D. Power 2022 Gas Utility Residential Customer Satisfaction Studysm and J.D. Power 2022 Electric Utility Residential Customer Satisfaction Studysm.

Key Points: 
  • Power 2022 Studies
    NEWARK, N.J., Dec. 14, 2022 /PRNewswire/ -- PSE&G has been recognized again for delivering award-winning customer satisfaction.
  • Power 2022 Gas Utility Residential Customer Satisfaction Study examines customer satisfaction across six factors: billing and payment, price, safety and reliability, corporate citizenship, communications and customer care.
  • Power 2022 Electric Utility Residential Customer Satisfaction Study examines customer satisfaction across six factors: billing and payment, price, power quality and reliability, corporate citizenship, communications and customer care.
  • Power 2022 Electric Utility Residential Customer Satisfaction Study compared 17 large utilities in the East and PSE&G swept all six study factors with first place rankings in each category.

EQS-News: The NIH Has Given BioRestorative Therapies A Stamp Of Approval

Retrieved on: 
Friday, November 11, 2022
Transfer, Federal, Qualcomm, QCOM, Lijun International Pharmaceutical (Holding) Co. Ltd., Innovation, Small Business Innovation Research, Biomedical engineering, Food, STTR, Diabetes, Advertising, Food and Drug Administration, Research, Adipose tissue, Department, NIH, Small Business Administration, Obesity, Biomedicine, Stem cell, SBIR, NASDAQ, Solution, National Institute, Company, PEG, B cell, Pain scale, Pain, Patient, Small business, National Institutes of Health, Washington University in St. Louis, Map, FDA, Pharmaceutical industry, Bank

BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.

Key Points: 
  • BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.
  • This fascinating opportunity presents a study that is highly suggestive of the potential outcomes for which they are currently processing.
  • BioRestorative Therapies Has Joined The Leagues Of 23andMe, Qualcomm and Naviscan
    In September 2021, BioRestorative was awarded a Small Business Technology Transfer (STTR) phase I grant for $256,000.
  • With the recent grants BioRestorative Therapies has received, the NIH has given the company a stamp of approval.

Bright Peak Presents New Therapeutics Highlighted by Multifunctional PD-1 Targeted Immunocytokines at SITC 2022

Retrieved on: 
Wednesday, November 9, 2022
SAN, GLOBE, IV, IND, FC, Tumor microenvironment, Huangshan, Immunotherapy, KDA, Cytokine, Development, Mouse, Half-life, CA, PD-1, Cancer, PEG, Patient, Therapy, Teff, ABS, Autoimmune disease, Animal, Society, Blood, SITC, Vaccine, Research

SAN DIEGO and BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a privately held biotechnology company developing next-generation, multifunctional precision immunotherapies for cancer and autoimmune disease, today announced the presentation of multiple new cancer immunotherapy agents at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held on November 9-12, 2022, in Boston, MA.

Key Points: 
  • "At SITC, we are introducing BPT567, the first ever PD1-IL18 immunocytokine.
  • Additionally, using the same functionally optimized IL-18 payload that has been incorporated into BPT567, Bright Peak has developed BPT543, a best-in-class, half-life extended IL-18 therapeutic designed for IV administration.
  • Bright Peak is a privately held biotechnology company based in Basel, Switzerland and San Diego, CA.
  • Bright Peak is funded by a syndicate of leading healthcare investors.